-62%

est. 2Y upside i

HealthcareAI & MLSeries A

Hello Patient is transforming healthcare communication through advanced conversational AI. After spending 3.5 years scaling Carbon Health's technology during its hypergrowth, their founding team witnessed firsthand how much clinical time gets wasted on basic communication—great clinicians buried in administrative work, patients frustrated by missed connections and phone tag.

Rank

#693

Sector

HealthTech, Artificial Intelligence

Est. Liquidity

~4Y

Data Quality

Data: Medium

Hello Patient operates in a rapidly growing and large AI in healthcare market, demonstrating impressive early traction with daily patient conversations scaling significantly.

Last updated: March 10, 2026

Bull (30%)+350%

Hello Patient successfully leverages its proprietary AI and 'service-as-software' model to become a dominant player in specialized healthcare communication niches, expanding rapidly beyond current specialties. This leads to significant market share capture in the large TAM, pushing its valuation to $450M+ by 2028, driven by strong revenue growth and strategic partnerships.

Base (30%)+100%

Hello Patient maintains its strong growth trajectory within its initial target specialties, securing additional funding rounds and fending off some competitive pressure. The company achieves a modest exit or further funding at a $200M valuation by 2028, representing a solid but not exceptional return for common stock holders after accounting for preferences.

Bear (40%)-80%

Dominant incumbents like Oracle Health or well-funded competitors such as Assort Health ($750M valuation) and EliseAI ($250M funding) aggressively enter or expand in Hello Patient's core market, leading to intense pricing pressure and slower-than-expected customer acquisition. This results in a down round or an exit at a significantly reduced valuation of $20M or less, severely impacting common stock value due to the $29M liquidation preference.

Est. time to liquidity~3.5 years

Preference Stack Risk

high

Funding Intensity

29%

Investors hold $29M in liquidation preferences ahead of common stock, representing 29% of the current $100M valuation.

Dilution Risk

high

As a Series A company, Hello Patient will likely undergo several more funding rounds, leading to further dilution of existing equity holders.

Secondary Liquidity

none

As a Series A company, there is currently no active secondary market for Hello Patient's common equity, and such liquidity is unlikely within a 2-year horizon.

Questions to Ask at the Interview

Strategic questions based on Hello Patient's data — designed to show you've done your homework.

  • 1

    “Given the rapid growth of competitors like Assort Health and EliseAI, how does Hello Patient plan to differentiate and defend its market share, particularly with its 'service-as-software' model?”

  • 2

    “What are the key revenue metrics (e.g., ARR, LTV/CAC) and growth projections for the next 12-24 months, and how does the company plan to expand its customer base beyond current specialties?”

  • 3

    “Considering the Series A funding and the current preference stack, what is the realistic timeline and strategy for future funding rounds and potential liquidity events for common stock holders?”

Community

Valuation Sentiment

Our model estimates -62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.